

9 March 2018

For immediate release

**OKYO Pharma Corporation
Result of General Meeting
Corporate Update**

OKYO Pharma Corporation (the “Company”) (AIM: OKYO) announces that the resolution put to Shareholders at the General Meeting held earlier today was duly passed. The resolution was proposed as a special resolution of Shareholders to:

- (a) change the name of the Company to OKYO Pharma Limited with effect from Migration;
- (b) approve the Migration to Guernsey; adopt, with effect from Migration, the Company's new memorandum and articles of incorporation compliant with Guernsey law, in place of the Company's existing memorandum and Articles;
- (c) disapply the pre-emption rights as set out in the New Articles; and
- (d) approve Cancellation of admission of its Ordinary Shares from trading on AIM.

As previously announced, cancellation of admission of its Ordinary Shares from trading on AIM will take effect at 7.00 a.m. on 23 March 2018.

Broker

As announced on 2 March 2018, the Company is seeking to appoint a new broker as soon as possible and a further announcement will be made when this appointment is made.

Special Dividend

The Company has finalised the arrangements for completion of the Special Dividend and the Board currently anticipates payments of the Special Dividend later this month.

For further information contact:

OKYO Pharma Corporation	Willy Simon	+44 (0)20 7382 8300
Beaumont Cornish Limited (Nominated Adviser)	Roland Cornish Michael Cornish	+44 (0)20 7628 3396

Further information is available on the Company's website: www.okyopharma.com

This announcement is inside information for the purposes of Article 7 of Regulation 596/2014. The person who arranged for the release of this announcement on behalf of the Company was Willy Simon, Director.

APPENDIX

DEFINITIONS

In this announcement, the following expressions have the following meanings unless the context otherwise requires:

“AIM”	the market of that name operated by the London Stock Exchange
“Articles”	articles of association or articles of incorporation of the Company in force from time to time including, with effect from Migration, the New Articles
“Cancellation”	the proposed cancellation of admission of the Ordinary Shares from trading on AIM
“Company” or “OKYO”	(i) as at the date of this document, OKYO Pharma Corporation, and (ii) subject to re-registration following Cancellation and completion of the Migration, OKYO Pharma Limited.
“Ferrum”	Ferrum Resources Limited
“Ferrum Shares”	the ordinary shares of no par value in the capital of Ferrum
“General Meeting”	the general meeting of the Company held at 10.00 a.m. on 9 March 2018
“Migration”	the continuation of the Company out of the British Virgin Islands and migration of the Company into Guernsey
“New Articles”	the proposed new articles of incorporation compliant with Guernsey law, to be adopted upon Migration in place of the Company’s existing articles of association
“Ordinary Shares”	ordinary shares of no par value in the capital of the Company
“Shareholders”	holders of Ordinary Shares
“Special Dividend”	the distribution of Ferrum Shares to Shareholders

ENDS